FDA Grants Priority Voucher for Rare Pediatric Disease Treatment Drug
Published Date: 12/19/2025
Notice
Summary
The FDA just gave Stealth BioTherapeutics a special priority review voucher for their rare pediatric disease drug, FORZINITY (elamipretide), approved in September 2025. This voucher speeds up future drug reviews, helping get important medicines to kids faster. It’s a big win for patients with Barth syndrome and could save time and money in drug development.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Priority Review Voucher Issued for FORZINITY
The FDA issued a priority review voucher to Stealth BioTherapeutics for FORZINITY (elamipretide), which the agency approved on September 19, 2025. FORZINITY is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg, and the voucher is intended to speed future drug reviews for rare pediatric disease products.
Voucher Lowers Development Time and Cost for Sponsor
The priority review voucher granted to the sponsor (Stealth BioTherapeutics) can shorten the review time for a future drug application and thus may save time and money in drug development for the sponsoring company.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-23408, Determination That EFFEXOR XR (Venlafaxine Hydrochloride) Extended-Release Capsule, 100 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that EFFEXOR XR 100 mg capsules were not taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of this medicine, helping patients access affordable options. No changes in safety rules or costs are expected, so things stay steady for doctors, patients, and pharmacies.
Next: 2025-23410, Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)
The FDA just gave the green light to KEYTRUDA QLEX, a new medicine for rare pediatric diseases, using a special priority review voucher. This means faster approval for important treatments that kids with rare diseases really need. The approval happened on September 19, 2025, and it shows the FDA’s commitment to speeding up life-saving drugs without extra cost to patients.